NRAS and cancer: In contrast, reduction of PIP5K1A in the HRAS-mutant and NRAS-mutant human cancer cell lines typically either had no consistent effect or even an increase in the number of viable cells, with the exception of TYKNU cells, in which all three PIP5K1A sgRNAs led to a decrease in cell number (Fig. 7a, b).